2026/07/31 更新

写真a

ナガオ ユカリ
長尾 有佳里
NAGAO Yukari
所属
医学部附属病院 産科婦人科 助教
大学院担当
大学院医学系研究科
職名
助教

学位 1

  1. 博士(医学) ( 2024年9月   名古屋大学 ) 

受賞 4

  1. 名古屋大学学術奨励賞

    2024年5月   名古屋大学  

  2. 日本産科婦人科学会優秀論文賞

    2024年3月   日本産科婦人科学会  

  3. 名古屋大学医学系研究科医学奨励賞

    2023年12月   名古屋大学  

  4. 日本癌学会若手研究者ポスター賞

    2021年10月   日本癌学会  

 

論文 29

  1. Drug library screening identifies colchicine and shikonin as therapeutic candidates for methotrexate-resistant choriocarcinoma

    Nishiko Y., Yoshida K., Yokoi A., Kitagawa M., Inami E., Yasui Y., Ishikawa T., Mizushima T., Yoshihara M., Mogi K., Nagao Y., Tamauchi S., Yoshikawa N., Yamamoto E., Niimi K., Kajiyama H.

    Biochemical and Biophysical Research Communications   831 巻   頁: 154317   2026年9月

     詳細を見る

    記述言語:英語   出版者・発行元:Biochemical and Biophysical Research Communications  

    Choriocarcinoma is a rare and aggressive form of gestational trophoblastic neoplasia, and methotrexate resistance remains a clinical challenge. In this study, we aimed to identify alternative therapeutic compounds that are effective against methotrexate-resistant choriocarcinoma by screening a drug library. Methotrexate-resistant JAR and JEG-3 cell lines were established by stepwise exposure to increasing concentrations of methotrexate. RNA sequencing confirmed increased expression of DHFR in the methotrexate-resistant JAR cells compared with the parental cells; however, gene silencing of DHFR mRNA did not sufficiently restore methotrexate sensitivity. Then, a two-step in vitro screening was conducted using a drug library consisting of more than 1000 compounds. In the primary screen, fifty-five compounds exhibited reduced cell viability to less than 25% in both cell lines. Based on known pharmacological classifications, 19 compounds were selected for secondary screening. Of these, colchicine and shikonin showed relatively higher cytotoxicity in both methotrexate-resistant cell lines. In vivo experiments showed a trend toward reduced tumor volume with shikonin and a longer time to the predefined study endpoint, whereas colchicine exhibited more limited antitumor activity. In conclusion, colchicine and shikonin demonstrated antitumor activity against methotrexate-resistant choriocarcinoma and warrant further investigation as potential therapeutic candidates.

    DOI: 10.1016/j.bbrc.2026.154317

    Scopus

    PubMed

  2. Rapid Enlargement of Vulvar Glomus Tumor After Needle Aspiration and Tumor Base Ligation Open Access

    Nagao, Y; Tamauchi, S; Yokoi, A; Yoshikawa, N; Niimi, K; Kajiyama, H

    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH   52 巻 ( 6 ) 頁: e70373   2026年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Obstetrics and Gynaecology Research  

    Vulvar glomus tumors are rare and typically benign, slow-growing tumors. Rapid enlargement is uncommon and may suggest malignancy or other atypical conditions. A 58-year-old postmenopausal woman noticed a small vulvar nodule. After needle aspiration at another hospital, significant bleeding occurred, requiring tumor base ligation. Although hemostasis was achieved, the mass subsequently continued to enlarge rapidly, prompting referral to our hospital. The lesion continued to enlarge gradually, so surgical excision was therefore performed. Histopathological findings confirmed a glomus tumor with atypical features, including a marked edematous stroma. The rapid enlargement was not attributed to malignancy, a hematoma, or an infection, but was considered to represent apparent growth associated with increased edema secondary to vascular congestion within the tumor. The present case highlights that the rapid enlargement of glomus tumor-related lesions does not necessarily indicate malignancy.

    DOI: 10.1111/jog.70373

    Open Access

    Web of Science

    Scopus

    PubMed

  3. Integrated immunophenotypic and ProMisE molecular profiling as predictors of immune checkpoint inhibitor response in recurrent endometrial cancer.

    Katayama K, Yoshikawa N, Liu W, Nakamura K, Hattori S, Kubokawa M, Iyoshi S, Yoshida K, Yoshihara M, Nagao Y, Tamauchi S, Yokoi A, Niimi K, Shimizu Y, Kawai Y, Utsumi F, Watanabe E, Suzuki S, Shibata K, Kajiyama H

    Cancer immunology, immunotherapy : CII     2026年6月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s00262-026-04414-y

    PubMed

  4. A novel extracellular vesicle isolation method based on cellulose nanofiber sheets Open Access

    Nagao, Y; Kajiyama, H; Yokoi, A

    EXTRACELLULAR VESICLES AND CIRCULATING NUCLEIC ACIDS   7 巻 ( 2 ) 頁: 535 - 544   2026年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Extracellular Vesicles and Circulating Nucleic Acids  

    Extracellular vesicles (EVs) circulate in body fluids, carrying molecular cargo from their parent cells and exerting diverse biological functions. Consequently, they have attracted considerable attention as biomarkers for disease detection and pathophysiological understanding and have emerged as potential therapeutic targets. Although the number of clinical trials involving EVs is increasing, major challenges remain, including methodological transparency and the heterogeneity of EV subpopulations. Various EV isolation methods are commonly employed, and the primary approaches are summarized in the MISEV2023 guidelines. Each method has advantages and disadvantages; however, most conventional approaches require relatively large liquid volumes (e.g., hundreds of microliters or more) to obtain sufficient EV yields for analysis. In recent years, novel technologies have been developed to overcome these limitations by addressing constraints related to sample volume, simplicity, and accuracy. One such innovation is the cellulose nanofiber-EV sheet, which we developed in 2023. This method enables the capture and stable storage of EVs from microvolumes of body fluids (e.g., approximately 10 µL). Two application methods are available: the attaching method, in which the EV sheet is applied to moist tissue surfaces, and the soaking method, in which the sheet is soaked into body fluids. Each method offers distinct advantages. Given their unique properties, EV sheets may contribute to biomarker analysis and facilitate new research directions across diverse fields. Continued advances in EV isolation and analytical platforms will be essential to support the safe clinical implementation of EV-based diagnostics and therapeutics.

    DOI: 10.20517/evcna.2025.187

    Open Access

    Web of Science

    Scopus

    PubMed

  5. Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum-taxane chemotherapy in ovarian cancer Open Access

    Yoshida, K; Araki, H; Yamada, Y; Masahashi, Y; Miyamoto, E; Katayama, K; Kubokawa, M; Mogi, K; Yoshihara, M; Nagao, Y; Tamauchi, S; Yokoi, A; Yoshikawa, N; Niimi, K; Kajiyama, H

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   31 巻 ( 8 ) 頁: 1576 - 1586   2026年5月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    Background: Germline BRCA (gBRCA) mutations and homologous recombination deficiency (HRD) are critical factors affecting treatment response; however, their association with hematologic toxicity remains controversial. This study assessed the interplay between these molecular features and hematologic adverse events during platinum–taxane chemotherapy. Methods: We retrospectively reviewed 62 patients with stage III–IV ovarian cancer between 2022 and 2024. After excluding 8 patients, 54 patients were stratified according to gBRCA and HRD status, and hematologic adverse events were evaluated for up to six treatment cycles. Moreover, meta-analysis was performed to integrate previously published data. Results: First, after excluding patients with uncertain gBRCA status, eight gBRCA mutation carriers were compared with 33 confirmed non-carriers. gBRCA mutation carriers tended to exhibit lower neutrophil counts during treatment; however, no statistically significant differences in hematologic toxicities were observed across treatment cycles. In the pooled meta-analysis, gBRCA mutation carriers demonstrated significantly increased odds of neutropenia (odds ratio [OR] 1.68, 95% confidence interval [CI] 1.16–2.44) and G-CSF use (OR 3.09, 95% CI 1.19–8.03), whereas no significant associations were observed for anemia, thrombocytopenia, dose delay, or dose reduction. Second, 23 HRD-positive patients and 15 HRD-negative patients were analyzed. HRD-positive patients did not demonstrate increased hematologic toxicity compared with HRD-negative patients. Although baseline hemoglobin levels were lower in HRD-positive patients, these differences preceded chemotherapy initiation. Conclusion: This study provides real-world evidence of a modestly increased risk of neutropenia and G-CSF use in gBRCA carriers during platinum–taxane chemotherapy; however, these differences did not appear to compromise treatment delivery.

    DOI: 10.1007/s10147-026-03065-4

    Open Access

    Web of Science

    Scopus

    PubMed

  6. 特集 皮膚と細胞外小胞 新しい細胞外小胞解析ツールとしてのEVシート

    長尾 有佳里, 横井 暁

    皮膚科   9 巻 ( 4 ) 頁: 313 - 319   2026年4月

     詳細を見る

    出版者・発行元:(有)科学評論社  

    DOI: 10.69337/d202604-094-05

    CiNii Research

  7. 妊娠性絨毛性腫瘍における絨毛癌診断スコアと FIGO 2000リスク分類の相関と治療成績

    吉田 泰斗, 吉田 康将, 新美 薫, 白﨑 茉莉, 安井 裕子, 茂木 一将, 吉原 雅人, 長尾 有佳里, 玉内 学志, 横井 暁, 芳川 修久, 山本 英子, 梶山 広明

    日本婦人科腫瘍学会雑誌   44 巻 ( 2 ) 頁: 146 - 152   2026年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:公益社団法人 日本婦人科腫瘍学会  

    <p>概要:妊娠性絨毛性腫瘍(GTN)は,胎盤栄養膜細胞の異常増殖を来す腫瘍性疾患であり,絨毛癌診断スコア・FIGO 2000リスク分類を用いた診断が行われる.これらの診断法では,臨床的絨毛癌はHigh-risk GTNに,臨床的侵入奇胎はLow-risk GTNに対応するが,診断の不一致症例も存在する.本研究は,1991~2023年に当院で治療を受けたGTN 273例を対象とし,両診断法の相関性と治療成績を報告する.結果として,臨床的絨毛癌かつHigh-risk GTN,臨床的侵入奇胎かつLow-risk GTNとなる症例の割合は92.2%であった.また,病理学的診断と絨毛癌診断スコアの一致率は92.7%であった.治療方針は,病理学的診断・絨毛癌診断スコアによって決定され,全生存率は絨毛癌群で84.9%,非絨毛癌群で99.5%であった.なお,絨毛癌かつLow-risk GTN症例は多剤併用療法を,侵入奇胎かつHigh-risk GTN症例は単剤療法を受け,全生存率は100%であった.総じて,両診断法は概ね一致するが,絨毛癌診断スコアの方が病理学的診断との一致率が高く,有用性が高いと考えられる.</p>

    DOI: 10.57291/jsgo.44.2_146

    CiNii Research

  8. Small-cell carcinoma of the cervix with acute-onset psychotic symptoms associated with clinically diagnosed ectopic ACTH production: a case report Open Access

    Ozaki, K; Fujino, J; Niimi, K; Iwata-Endo, K; Otsuka, N; Kobayashi, T; Yoshida, K; Mogi, K; Yoshihara, M; Nagao, Y; Tamauchi, S; Yokoi, A; Yoshikawa, N; Kajiyama, H

    FRONTIERS IN ONCOLOGY   16 巻   頁: 1684861   2026年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Frontiers in Oncology  

    Small-cell carcinoma of the cervix (SCCC) is a rare and highly aggressive histological subtype of cervical cancer, associated with poor prognosis. SCCC is histologically classified as a neuroendocrine tumor and has the potential to produce ectopic hormones, leading to various paraneoplastic syndromes. This report is a rare case of recurrent SCCC presenting with psychiatric symptoms due to endogenous Cushing’s syndrome caused by ectopic adrenocorticotropic hormone (ACTH) production. The patient initially developed mood and behavioral disturbances as the disease progressed, leading to hospitalization under the suspicion of a primary psychiatric disorder. However, further evaluation, prompted by the discovery of severe hypokalemia, revealed Cushing’s syndrome associated with clinically diagnosed ectopic ACTH production in the setting of recurrent disease. Her psychiatric symptoms rapidly remitted following the administration of a cortisol synthesis inhibitor. This case highlights the importance of considering endocrine disorders as potential causes of psychiatric manifestations in patients with cancer, particularly those with neuroendocrine tumors such as SCCC. Acute and marked elevation of endogenous cortisol can induce distinct psychiatric symptoms, such as manic features and grandiose delusions, that often respond better to endocrine treatment aimed at normalizing cortisol levels rather than to antipsychotic therapy alone. Clinicians should be aware of this rare but important clinical presentation as timely diagnosis and management can improve patient outcomes.

    DOI: 10.3389/fonc.2026.1684861

    Open Access

    Web of Science

    Scopus

    PubMed

  9. Natural-killer-cell-dominant immune landscape and HLA-E-mediated immune evasion in choriocarcinoma 査読有り Open Access

    Shibata, M; Yoshida, K; Yasui, Y; Nishiko, Y; Hattori, S; Nakamura, K; Koya, Y; Yamamoto, Y; Suzuki, K; Yoshihara, M; Nagao, Y; Tamauchi, S; Yokoi, A; Yoshikawa, N; Nishino, K; Yamamoto, E; Niimi, K; Kajiyama, H

    PLACENTA   174 巻   頁: 9 - 18   2026年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Placenta  

    Objective: Choriocarcinoma is a rare cancer associated with antecedent pregnancy. Therefore, its development may be influenced by an immune-evasive tumor microenvironment. In this study, we focused on natural killer (NK) cells to elucidate the immune microenvironment of choriocarcinoma. Methods: Peripheral blood and intratumoral NK cells were isolated from six samples of four patients with choriocarcinoma. Flow cytometry was used to analyze the NK cell proportion. Immunohistochemistry was performed to assess the expression of NK cell inhibitory ligands using choriocarcinoma tissues from 17 patients. In addition, choriocarcinoma cell lines (JAR, BeWo, and JEG-3) were cocultured with interleukin-2-stimulated NK cells, and loss-of-function analyses of HLA-E were conducted to investigate the impact of NK cells on choriocarcinoma cells. Results: Flow cytometry revealed that NK cells were more abundant in choriocarcinoma tissues than in the peripheral blood. Immunohistochemistry confirmed the expression of NK cell inhibitory ligands, including HLA-E. Moreover, JAR cells were cocultured with NK cells, and viable JAR cells were isolated by flow cytometry. Subsequent mRNA sequencing showed that HLA-E was upregulated, and multiple cytokine-related pathways were activated in the cocultured JAR cells compared with monocultured JAR cells. Functional assays demonstrated that HLA-E knockdown enhanced NK-cell-mediated cytotoxicity, whereas interferon-gamma treatment increased HLA-E expression and promoted tumor cell survival. Conclusion: These findings suggest that NK cells may play an important role in the tumor immune microenvironment of choriocarcinoma through HLA-E expression.

    DOI: 10.1016/j.placenta.2025.11.012

    Open Access

    Web of Science

    Scopus

    PubMed

  10. Risk factors for recurrent cases of early-stage uterine sarcoma after complete surgical resection 査読有り Open Access

    Nagao, Y; Yokoi, A; Yoshida, K; Yoshihara, M; Tamauchi, S; Yoshikawa, N; Niimi, K; Kajiyama, H

    BMC CANCER   26 巻 ( 1 )   2026年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BMC Cancer  

    Background: Uterine sarcoma has an inferior prognosis and high recurrence rate among gynecological malignancies, even in early-stage cases with complete resection. However, the risk factors for recurrence remain poorly understood. This study aimed to identify risk factors associated with recurrence in early-stage uterine sarcoma. Methods: Among 97 patients with uterine sarcoma treated at our institution between January 2007 and June 2023, we retrospectively investigated 55 patients of the following five histological types: uterine leiomyosarcoma (ULMS), low- or high-grade endometrial stromal sarcoma (LG-ESS or HG-ESS), adenosarcoma, and smooth muscle tumor of uncertain malignant potential (STUMP). Risk factors were compared between the recurrence and non-recurrence groups using univariate analysis, and recurrence rates, time to recurrence, progression-free survival (PFS), and overall survival (OS) were examined. Results: The median age of 55 patients was 48 years, and the most common initial symptom was abdominal pain or abdominal mass awareness (29.4%), followed by abnormal bleeding in 25.5% of the patients. The median tumor size was 9.7 cm, and stage I cases were 64.8% of the total. Histological types were 28 ULMS, 13 LG-ESS, 8 STUMP, 5 HG-ESS, and one adenosarcoma. Among stage I cases, ULMS had a recurrence rate of 81.3% with a median time to recurrence of 12.4 months, while LG-ESS had a recurrence rate of 30% with a median time to recurrence of 41.1 months. A high mitotic count was significantly associated with recurrence in stage I ULMS (p = 0.044). Other surgical pathological findings, such as lymphovascular space invasion, MIB-1 positive rate, and necrosis, and surgical factors, such as myomectomy and ovarian preservation, showed no statistically significant differences but were higher in the recurrence cases. The 5-year PFS rates in stage I ULMS and LG-ESS groups were 31.3% and 75%, and the 5-year OS rates were 68.5% and 100%, respectively. Conclusions: In stage I ULMS, a high mitotic count was associated with an increased risk of recurrence after complete surgical resection.

    DOI: 10.1186/s12885-026-15618-x

    Open Access

    Web of Science

    Scopus

    PubMed

  11. Application of EV sheets to realize ideal extracellular vesicle biomarker development in ovarian cancer

    Nagao, Y; Yokoi, A; Yoshida, K; Kitagawa, M; Inami, E; Suzuki, K; Yoshihara, M; Tamauchi, S; Yoshikawa, N; Niimi, K; Yasui, T; Kajiyama, H; Otani, N; Takahashi, C; Kohno, T; Fujita, Y; Totsuka, Y; Nannya, Y; Kiyokawa, E; Gotoh, N

    CANCER SCIENCE   117 巻   頁: 165 - 165   2026年1月

     詳細を見る

  12. Changes in glycosylation enzymes in mesothelial cells adjacent to adipose tissue and progression of ovarian cancer

    Kunishima, A; Iyoshi, S; Yoshikawa, M; Miyamoto, E; Fujimoto, H; Yoshida, K; Mogi, K; Yoshihara, M; Tamauchi, S; Nagao, Y; Yokoi, A; Yoshikawa, N; Niimi, K; Kajiyama, H

    CANCER SCIENCE   117 巻   頁: 798 - 798   2026年1月

     詳細を見る

  13. Unveiling a Novel Role of Mesothelial Glycocalyx in Peritoneal Metastasis of Ovarian Cancer

    Mogi, K; Yoshikawa, M; Kunishima, A; Miyamoto, E; Koya, Y; Yamakita, Y; Fujimoto, H; Iyoshi, S; Yoshida, K; Yoshihara, M; Nagao, Y; Tamauchi, S; Yokoi, A; Yoshikawa, N; Niimi, K; Kajiyama, H

    CANCER SCIENCE   117 巻   頁: 1196 - 1196   2026年1月

     詳細を見る

  14. Investigation of Choriocarcinoma-Associated miRNAs Through Small RNA Sequencing

    Yoshida, K; Iyoshi, S; Mogi, K; Yoshihara, M; Nagao, Y; Tamauchi, S; Yokoi, A; Niimi, K; Kajiyama, H

    CANCER SCIENCE   117 巻   頁: 2132 - 2132   2026年1月

     詳細を見る

  15. Downregulation of Chromosome 19 miRNA Cluster and the Tumor-Suppressive Role of miR-517a-3p in Choriocarcinoma 査読有り Open Access

    Nishiko, Y; Yoshida, K; Yasui, Y; Yokoi, A; Kitagawa, M; Inami, E; Yoshihara, M; Mogi, K; Nagao, Y; Tamauchi, S; Yoshikawa, N; Nishino, K; Yamamoto, E; Niimi, K; Kajiyama, H

    CANCER SCIENCE   116 巻 ( 12 ) 頁: 3473 - 3486   2025年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Science  

    Choriocarcinoma is a rare gynecologic malignancy. MicroRNAs, which are noncoding RNAs approximately 22 nucleotides in length, are known to regulate gene expression and play important roles in various cancers; however, their functions in choriocarcinoma remain largely unknown. This study aimed to identify disease-specific microRNAs involved in choriocarcinoma development. Eleven cases of choriocarcinoma and five cases of complete hydatidiform mole treated at our institution were analyzed. Total RNA was extracted from trophoblast cells in formalin-fixed, paraffin-embedded specimens using laser capture microdissection, and microRNA sequencing was performed. The analysis revealed that 87 microRNAs were significantly upregulated, whereas 28 were downregulated in choriocarcinoma compared to complete hydatidiform mole. Notably, 13 of the 28 downregulated microRNAs belonged to the chromosome 19 microRNA cluster. In vitro experiments demonstrated that overexpression of miR-517a-3p, a representative member of this cluster, significantly suppressed cell proliferation, migration, and invasion in JEG-3 and BeWo cell lines. Further transcriptome sequencing and computational analysis identified SRSF1 as a target gene of miR-517a-3p, which was validated by dual-luciferase reporter assays. Knockdown of SRSF1 also led to significant reductions in proliferation, migration, and invasion, supporting its functional relevance. Immunohistochemical analysis confirmed that SRSF1 protein was highly expressed in choriocarcinoma tissues compared to complete hydatidiform mole. These findings indicate that downregulation of the chromosome 19 microRNA cluster is a characteristic feature of choriocarcinoma and that miR-517a-3p functions as a tumor suppressor by directly regulating SRSF1 expression.

    DOI: 10.1111/cas.70207

    Open Access

    Web of Science

    Scopus

    PubMed

  16. Exploring drug resistance via intercellular crosstalk using spatial transcriptomics in high-grade serous ovarian carcinoma 査読有り Open Access

    Suzuki, H; Yoshida, K; Yokoi, A; Suzuki, K; Hirano, Y; Kitagawa, M; Asano-Inami, E; Yoshihara, M; Nagao, Y; Tamauchi, S; Yoshikawa, N; Kajiyama, H; Yamamoto, Y

    NPJ PRECISION ONCOLOGY   9 巻 ( 1 ) 頁: 345   2025年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Npj Precision Oncology  

    Poly(ADP-ribose) polymerase inhibitors (PARPis) have improved the prognosis of patients with high-grade serous ovarian carcinoma (HGSOC). However, PARPis are not effective for all HGSOC patients. Spatial transcriptomics is a powerful tool for characterizing the tumor microenvironment. We used Visium to analyze eight tumor samples from HGSOC patients with clinical information on PARPi sensitivity. Two complementary analyses were performed: an integrated analysis across all samples, without considering spatial information, and an analysis with spatial information within each sample. Both approaches indicated that midkine (MDK) signaling is involved in PARPi resistance. Furthermore, we identified receptors that enhance MDK signaling in cancer cells. To assess the generalizability of this finding, we deconvolved bulk RNA-sequencing data using single-cell RNA-sequencing data as a reference to examine the relationship between receptor expression levels and overall survival (OS). This analysis revealed that high SDC4 expression in cancer cells is associated with poor OS in HGSOC patients.

    DOI: 10.1038/s41698-025-01122-1

    Open Access

    Web of Science

    Scopus

    PubMed

  17. Application of multimodal integration to develop preoperative diagnostic models for borderline and malignant ovarian tumors 査読有り Open Access

    Kunishima, A; Inaba, D; Iyoshi, S; Ikeda, Y; Goto, M; Muramatsu, R; Hashimoto, M; Yoshida, K; Mogi, K; Yoshihara, M; Nagao, Y; Tamauchi, S; Yokoi, A; Yoshikawa, N; Niimi, K; Koizumi, N; Kajiyama, H

    SCIENTIFIC REPORTS   15 巻 ( 1 ) 頁: 37114   2025年10月

     詳細を見る

    記述言語:英語   出版者・発行元:Scientific Reports  

    Malignant ovarian tumors (MOTs) and borderline ovarian tumors (BOTs) differ in treatment strategies and prognosis. However, accurate preoperative diagnosis remains challenging, and improving diagnostic accuracy is crucial. We developed and validated a system using artificial intelligence (AI) to integrate machine learning (ML) models based on blood test data and deep learning (DL) models based on magnetic resonance imaging (MRI) findings to distinguish between MOT and BOT. We analyzed 78 patients with malignant serous ovarian tumors and 31 with borderline serous ovarian tumors treated at our institution. A classification model was developed using ML for blood test data, and a DL model was constructed using MRI data. By integrating these models, we developed three fusion models as multimodal diagnostic AI and compared them with standalone models. The performance was evaluated using precision, recall, and accuracy. The classification model using Light Gradient Boosting Machine achieved an accuracy of 0.825, and the DL model using Visual Geometry Group 16-layer network achieved an accuracy of 0.722 for discriminating BOT from MOT. The intermediate, late, and dense fusion models achieved accuracies of 0.809, 0.776, and 0.825, respectively. Integrating multimodal information such as blood test and imaging data may enhance learning efficiency and improve diagnostic accuracy.

    DOI: 10.1038/s41598-025-21128-w

    Open Access

    Web of Science

    Scopus

    PubMed

  18. Proteomic Profiling of Bacterial Extracellular Vesicles for Exploring Ovarian Cancer Biomarkers 査読有り Open Access

    Asano-Inami, E; Yokoi, A; Yoshida, K; Taki, K; Kitagawa, M; Suzuki, K; Uekusa, R; Nagao, Y; Yoshikawa, N; Niimi, K; Yamamoto, Y; Kajiyama, H

    JOURNAL OF EXTRACELLULAR BIOLOGY   4 巻 ( 10 ) 頁: e70073   2025年10月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Extracellular Biology  

    Extracellular vesicles (EVs) are present in body fluids and act as disease biomarkers. Emerging evidence has proven that EVs are released not only from mammalian cells but also from bacteria. Ovarian cancer has a dismal prognosis because of difficulties in early detection. This study aimed to identify bacterial EV (BEV) proteins associated with ovarian cancer. Fifteen patients with ovarian cancer or non-cancer were recruited, and EVs were isolated from the ascites. BEVs were recovered from seven in vitro-cultured strains of bacteria present in the vaginal microbiota, and LC-MS/MS analysis was performed. The detected peptide data were annotated to both human and bacterial references, and the human data showed that the profiles of cancer EVs were distinct from those of patients with non-cancer. As analysed by bacterial proteins, P15636_Protease1 was found as the BEV-associated protein highly expressed in patients with cancer. To distinguish patients with cancer, the area under the curve was 0.88 (95% CI, 0.64–1.00). In addition, homology analysis showed that P15636_Protease1 is a unique protein only detected in bacteria. In this study, ovarian cancer-specific bacterial proteins were identified on EVs, and BEVs in bodily fluids are promising in the discovery of disease biomarkers.

    DOI: 10.1002/jex2.70073

    Open Access

    Web of Science

    Scopus

    PubMed

  19. Tumor growth direction predicts surgical difficulty in large uterine fibroids: A retrospective imaging-based study 査読有り

    Tamauchi, S; Niimi, K; Iyoshi, S; Yoshida, K; Mogi, K; Yoshihara, M; Nagao, Y; Yokoi, A; Yoshikawa, N; Kajiyama, H

    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH   51 巻 ( 7 ) 頁: e70013   2025年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Obstetrics and Gynaecology Research  

    Objective: To identify preoperative imaging features associated with retroperitoneal growth of large uterine fibroids and evaluate their impact on surgical outcomes. Methods: This retrospective study included 20 patients who underwent hysterectomy for uterine fibroids measuring ≥10 cm between 2014 and 2024. Preoperative CT or MRI was evaluated for four features: bladder displacement, sigmoid colon deviation, cecal displacement, and hydronephrosis. Tumor growth direction (intraperitoneal vs. retroperitoneal) was determined intraoperatively. Operative time, blood loss, and complications were compared between groups. Results: Eight tumors exhibited retroperitoneal growth. Bladder displacement, cecal shift, sigmoid colon deviation, and hydronephrosis were significantly more common in retroperitoneal cases (all p < 0.05). Retroperitoneal tumors were associated with significantly greater median blood loss (1591 mL vs. 651 mL, p = 0.043), although operative time did not differ significantly (301 vs. 232 min, p = 0.237). Organ injury or resection occurred only in the retroperitoneal group. A bubble plot illustrated the trend of increased surgical burden in retroperitoneal cases. Conclusion: Retroperitoneal growth of large uterine fibroids is associated with increased intraoperative blood loss and surgical complexity. Four simple imaging features may serve as reliable indicators of growth direction and help guide preoperative planning.

    DOI: 10.1111/jog.70013

    Web of Science

    Scopus

    PubMed

  20. Targeting JAK/STAT pathway via extracellular vesicles overcomes platinum resistance in ovarian cancer

    Suzuki, K; Yokoi, A; Yoshida, K; Kitagawa, M; Nagao, Y; Kitai, M; Sudo, T; Yamamoto, Y; Kajiyama, H

    CANCER SCIENCE   116 巻   頁: 1291 - 1291   2025年1月

     詳細を見る

  21. The functional impact of intraperitoneal extracellular vesicle heterogeneity on ovarian cancer progression

    Hishikawa, R; Yokoi, A; Yoshida, K; Suzuki, K; Nagao, Y; Kitagawa, M; Yoshikawa, N; Niimi, K; Kitai, M; Yamaguchi, S; Kajiyama, H

    CANCER SCIENCE   116 巻   頁: 242 - 242   2025年1月

     詳細を見る

  22. 子宮平滑筋肉腫における発がんメカニズム解析と新規治療戦略の同定 Open Access

    長尾 有佳里, 横井 暁, 吉田 康将, 北川 雅美, 山本 雄介, 加藤 友康, 梶山 広明

    日本婦人科腫瘍学会雑誌   42 巻 ( 2 ) 頁: 75 - 85   2024年4月

     詳細を見る

    担当区分:筆頭著者   記述言語:日本語   出版者・発行元:公益社団法人 日本婦人科腫瘍学会  

    DOI: 10.57291/jsgo.42.2_75

    Open Access

    CiNii Research

  23. Uterine leiomyosarcoma cell-derived extracellular vesicles induce the formation of cancer-associated fibroblasts 査読有り

    Nagao, Y; Yokoi, A; Yoshida, K; Kitagawa, M; Asano-Inami, E; Kato, T; Ishikawa, M; Yamamoto, Y; Kajiyama, H

    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE   1870 巻 ( 4 ) 頁: 167103   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Biochimica Et Biophysica Acta Molecular Basis of Disease  

    Objective: Uterine leiomyosarcoma (ULMS) is a rare malignant tumor, which is aggressive, and has a poor prognosis even during its early stages. Extracellular vesicles (EVs) carry cargo, such as microRNAs (miRNAs), which are involved in intercellular communication in the tumor microenvironment and other processes. Because there are no studies on EV-related miRNAs in ULMS, we identified EV-related miRNAs in ULMS and examined their function. Methods: Small EVs (sEVs) and medium/large EVs (m/lEVs) were extracted from ULMS cells by ultracentrifugation and their basic characteristics were evaluated. Then, small RNA sequencing was done to obtain EV-related miRNA profiles. Next, miRNA expression levels in sera and tissues of ULMS patients were compared with those of myoma patients. Results: miR-654-3p and miR-369-3p were indicated to be highly expressed in both sera and tissues of ULMS patients. These two miRNAs are also highly expressed in ULMS cell lines and ULMS-derived EVs. Some cancer-associated fibroblast (CAF) markers were increased when fibroblasts were treated with ULMS-derived EVs. Furthermore, fibroblasts took up EVs derived from ULMS as determined by confocal laser microscopy. In addition, the transfection of the two candidate miRNAs into fibroblasts significantly increased some CAF markers, particularly ACTA2. Conclusion: miR-654-3p and miR-369-3p are highly expressed in ULMS-derived EVs, indicating that these EV-related miRNAs induce the formation of cancer-associated fibroblasts.

    DOI: 10.1016/j.bbadis.2024.167103

    Web of Science

    Scopus

    PubMed

  24. Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma

    Nagao, Y; Yokoi, A; Yoshida, K; Sugiyama, M; Watanabe, E; Kitagawa, M; Yoshihara, M; Tamauchi, S; Kato, T; Ishikawa, M; Yamamoto, Y; Kajiyama, H

    CANCER SCIENCE   115 巻   頁: 1232 - 1232   2024年3月

     詳細を見る

  25. Therapeutic potential of extracellular vesicles from adipose-derived stem cells in ovarian cancer

    Suzuki, H; Yokoi, A; Uno, K; Yoshida, K; Inami, E; Kitagawa, M; Suzuki, K; Nagao, Y; Yamamoto, Y; Kajiyama, H

    CANCER SCIENCE   115 巻   頁: 1011 - 1011   2024年3月

     詳細を見る

  26. Spatial exosome analysis using cellulose nanofiber sheets reveals the location heterogeneity of extracellular vesicles 査読有り

    NATURE COMMUNICATIONS   14 巻 ( 1 ) 頁: 6915   2023年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  27. Small Extracellular Vesicles from adipose-derived stem cells suppress cell proliferation by delivering the let-7 family of microRNAs in ovarian cancer 査読有り

    Hironori Suzuki, Akira Yokoi, Kaname Uno, Kosuke Yoshida, Masami Kitagawa, Eri Asano-Inami, Seiko Matsuo, Yukari Nagao, Kazuhiro Suzuki, Kae Nakamura, Masato Yoshihara, Satoshi Tamauchi, Yusuke Shimizu, Yoshiki Ikeda, Nobuhisa Yoshikawa, Hiroaki Kajiyama, Yusuke Yamamoto

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   680 巻   頁: 211 - 219   2023年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  28. Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma 査読有り

    Yukari Nagao, Akira Yokoi, Kosuke Yoshida, Mai Sugiyama, Eri Watanabe, Kae Nakamura, Masami Kitagawa, Eri Asano-Inami, Yoshihiro Koya, Masato Yoshihara, Satoshi Tamauchi, Yusuke Shimizu, Yoshiki Ikeda, Nobuhisa Yoshikawa, Tomoyasu Kato, Yusuke Yamamoto, Hiroaki Kajiyama

    PHARMACOLOGICAL RESEARCH   189 巻   頁: 106693   2023年3月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

  29. Clinical effects of cervical conization with positive margins in cervical cancer 査読有り

    Yukari Nagao, Akira Yokoi, Kosuke Yoshida, Masanori Sumi, Masato Yoshihara, Satoshi Tamauchi, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Kaoru Niimi, Hiroaki Kajiyama

    SCIENTIFIC REPORTS   11 巻 ( 1 ) 頁: 23288   2021年12月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

▼全件表示

共同研究・競争的資金等の研究課題 2

  1. EVシートによる革新的卵巣がん細胞外小胞解析と臨床応用

    2025年度JCA-KFCR若手研究助成 

      詳細を見る

    担当区分:研究代表者 

    配分額:1000000円

  2. EVシートによる卵巣癌患者細胞外小胞バイオマーカー確立

    医学研究助成 

      詳細を見る

    配分額:500000円

科研費 2

  1. 次世代型EV抽出ツールを応用した革新的卵巣癌バイオマーカー戦略開発研究

    研究課題/研究課題番号:26K20015  2026年4月 - 2029年3月

    科学研究費助成事業  若手研究

    長尾 有佳里

      詳細を見る

    担当区分:研究代表者 

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    細胞由来情報を搭載し体液中を循環し機能する、細胞外小胞(Extracellular vesicle、EV)はバイオマーカーや治療標的として注目される。近年我々が開発した、微細な孔をもつセルロースナノファイバーで成るEVシートは、微量な体液からのEV捕捉と安定的保存を可能とし、これまでのEV精製の概念を覆す革新的な方法である。本研究では、EVシートの利点を最大限に生かした新しいEVトランスレーショナル研究開発として、卵巣癌の悪性化メカニズムに関わる卵管采由来EVの生物学的機能や転移巣へのEVの関与解明とともに、卵巣癌の診断や治療に関わる多角的なバイオマーカーを確立し臨床応用へと橋渡しを行う。

  2. EVシートによる革新的卵巣癌細胞外小胞解析と臨床応用

    研究課題/研究課題番号:25K23841  2025年7月 - 2027年3月

    科学研究費助成事業  研究活動スタート支援

    長尾 有佳里

      詳細を見る

    担当区分:研究代表者 

    配分額:2730000円 ( 直接経費:2100000円 、 間接経費:630000円 )

    細胞外小胞(Extracellular vesicle、EV)は細胞由来情報を搭載し体液中を循環し機能する。近年我々は微量体液からのEV捕捉と安定的保存を可能とした次世代EV回収法であるEVシートを開発した。EVシートを体液に浸すソーキング法と術中に腹腔内各臓器に貼付するアタッチング法の2種の利用法があり、回収したEVの解析が可能である。本研究では、EVシートの利点を最大限に生かし、卵巣癌の早期診断、病期分類、治療効果予測、再発予測などのバイオマーカーを確立し、卵巣癌の悪性化メカニズムに関わる卵管采由来EVの生物学的特徴や転移巣へのEVの関与を解明する。

産業財産権 1

  1. 卵巣癌を検査する方法

     詳細を見る

    出願番号:2024-185708  出願日:2024年10月